Basic Information

Common name
B-hCD112 MC38
Catalog number
321947
Aliases
HVEB; PRR2; NECTIN2; PVRL2; PVRR2
Disease
Colon carcinoma
Organism
Mouse
Strain
C57BL/6
Tissue types
Colon
Tissue
Colon
Application
B-hCD112 MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.
NCBI Gene ID

Description

The mouse Cd112 gene was replaced by human CD112 coding sequence in B-hCD112 MC38 cells. Human CD112 is highly expressed on the surface of B-hCD112 MC38 cells.

Targeting strategy

Gene targeting strategy for B-hCD112 MC38 cells. The exogenous promoter and chimeric CD112 containing mouse signal peptide, human extracellular region and mouse transmembrane and intracellular region was inserted to replace part of murine exon 2 and all of exon 3. The insertion disrupts the endogenous murine Cd112 gene, resulting in a non-functional transcript.

Protein expression analysis

CD112 expression analysis in B-hCD112 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hCD112 MC38 cultures were stained with species-specific anti-CD112 antibody. Mouse CD112 was detected on the surface of wild-type MC38 cells. Human CD112 was detected on the surface of B-hCD112 MC38 cells. The 1-E01 clone of B-hCD112 MC38 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

Subcutaneous homograft tumor growth of B-hCD112 MC38 cells. B-hCD112 MC38 cells (5×105) and wild-type MC38 cells (5×105) were subcutaneously implanted into C57BL/6 mice (female, 8-week-old). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hCD112 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

B-hCD112 MC38 cells were subcutaneously transplanted into C57BL/6 mice, and on 35 days post inoculation, tumor cells were harvested and assessed for human CD112 expression by flow cytometry. As shown, human CD112 was highly expressed on the surface of tumor cells. Therefore, B-hCD112 MC38 cells can be used for in vivo efficacy studies of novel CD112 therapeutics.

Back to top